focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CORRECT: Coral Products buys Ecodeck; Evgen Pharma recruits

Thu, 13th Oct 2022 17:55

(Correcting Harmony Energy Income Trust's use of funds.)

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Harmony Energy Income Trust PLC - London-based investment company focused on energy projects - Raises GBP15 million in an issue of 15.0 million shares at a price of 100 pence each. Plans to use the funds to fund its pipeline of 2-hour duration battery energy storage systems projects. "The net proceeds of the issue, together with not less than 7 million C shares to be issued to Harmony Energy as consideration, will enable the company to exercise its right of first refusal on these projects and secure them at the attractive entry point agreed pursuant to the pipeline agreement," the company says.

----------

Castillo Copper Ltd - Perth, Australia-based exploration company focused on copper across Australia and Zambia - Completes four drill holes for 488 meters at the Tors Tank prospect, within its BHA project's east zone. Says all four holes have hit targeted cobalt mineralisation zones. Looks forward to remaining assay results. "The drilling campaign has got off to an excellent start, with initial interpretations from the geology team confirming that targeted cobalt zones have been intersected. Moreover, whilst subject to final assay results, the board is delighted to learn that significant pegmatite zones have been intersected which could potentially host rare earth elements," Managing Director Dennis Jensen comments.

----------

AssetCo PLC - London-based advisory and asset management firm - Appoints Numis Securities Ltd to continue with its share repurchase programme. Accelerates its existing GBP7.5 million share repurchase programme.

----------

Condor Gold PLC - mine developer in Nicaragua - Appoints Jim Mellon as non-executive chair. He was non-executive director for several years and is the largest shareholder with a 19% stake.

----------

TomCo Energy PLC - London-based oil explorer in the US state of Utah - Gets a conversion notice from its convertible loan subscriber to convert the remaining GBP175,000 principal amount of the first tranche of the convertible loan, together with GBP75,000 principal amount of the second tranche of the convertible loan and the associated interest on both principal amounts of GBP12,500 into new shares.

----------

Evgen Pharma PLC- Cheshire, England-based drug development company - Starts recruitment for the pharmacokinetic/pharmacodynamic trial in healthy volunteers and decides to start an investigator sponsored clinical study for its glioblastoma programme. Says the purpose of the healthy volunteers study is to examine the performance of Evgen's new enteric coated tablet formulation of lead asset SFX-01.

----------

Coral Products PLC - Manchester-based plastic products maker - Acquires Ecodeck Grids Ltd for a consideration of up to GBP5.6 million. GBP3.4 million will be paid in cash. Further, it will issue of 6.3 million shares in the company at a price of 16 pence per ordinary share. "This acquisition further reinforces our focus on niche, specialist operators in the plastics sector. We have an opportunity to leverage Ecodeck's online platform for other group eco-friendly products. We see significant scope to add value as we integrate the business into the Group - the acquisition continues to broaden our group's product offering and greatly enhances our available market opportunities. We expect this acquisition will be earnings enhancing in its first year," Executive Chair Joe Grimmond says.

----------

Palace Capital PLC - London-based property investment company - In the first half to September 30, rent collection was 99% and occupancy remained "stable" at 89%, up from 98 and flat at 89% respectively. Completes seven new lettings, six lease renewals and ten rent reviews, generating contracted revenue of GBP2.2 million. "At an operational level the company has made steady progress with its asset management activities and in reducing its level of gross debt and its cost base. However, the significant volatility and uncertainty in financial markets with the prospect of significant increases in interest rates has adversely impacted the commercial property market in relation to investment activity resulting in a re-pricing of assets compared with the position earlier in the year. Therefore, the board has decided to pause the timing of significant property disposals for the time being," Executive Chair Steven Owen says.

----------

Canadian Overseas Petroleum Ltd - Calgary, Canada-based oil and gas company operating in Nigeria and US state of Wyoming - receives gas flaring approval for the Barron Flats Shannon unit from the Wyoming Oil and Gas Conservation Commission at a hearing.

----------

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
27 Jul 2018 13:14

Friday broker round-up

(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.

Read more
26 Jul 2018 12:54

Evgen Pharma Expects Final Results From Clinical Trials At End Of Year

LONDON (Alliance News) - Evgen Pharma PLC said Thursday it expects to receive the final read-out from two clinical trials by the end of 2018.The drug development company said at its annual

Read more
25 Jul 2018 14:48

Evgen concludes patient recruitment in STEM breast cancer trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer, it announced on Wednesday.

Read more
25 Jul 2018 13:57

Wednesday broker round-up

(Sharecast News) - Unite Group: Numis downgrades to hold with a target price of 900p.

Read more
25 Jul 2018 13:31

Evgen Pharma Metastatic Breast Cancer Trial Ends Patient Recruitment

LONDON (Alliance News) - Evgen Pharma PLC said Wednesday it has concluded its patient recruitment for its STEM Phase IIa trial of SFX-01 in metastatic breast cancer.Following the favourable

Read more
19 Jul 2018 16:21

UK Shareholder Meetings Calendar - Next 7 Days

Friday 20 JulyHomeserveKCOM GroupMonday 23 JulyEthernity Energy 24

Read more
13 Jun 2018 10:46

Evgen Pharma Annual Loss Narrows As It Continues Phase II Trials

LONDON (Alliance News) - Clinical drug development company Evgen Pharma PLC said Wednesday its annual loss narrowed in line with expectations.Evgen, which focuses on cancer and neurological

Read more
11 Jun 2018 11:33

Evgen STEM Interim Trial Result Show "Signs Of Anti-Tumour Activity"

LONDON (Alliance News) - Evgen Pharma PLC said Monday its STEM trial showed "early signs of anti-tumour activity" in breast cancer patients.STEM is the company's study of in a

Read more
2 May 2018 11:15

Evgen Pharma Gets European Patent For Sulforaphane Stablising Method

LONDON (Alliance News) - Drug development company Evgen Pharma said Wednesday that it has secured a European patent recognising its intellectual property for a method of stabilising sulforaphane,

Read more
20 Mar 2018 13:56

Evgen Pharma Begins Research Partnership With Imperial College London

LONDON (Alliance News) - Drug development company Evgen Pharma PLC has started a new research collaboration with Imperial College London focusing on SFX-01, the company's

Read more
13 Feb 2017 08:21

Evgen Pharma signs service agreement with drug development corsortium

(ShareCast News) - AIM-listed Evgen Pharma has signed a services agreement with a consortium of Cheshire-based drug developments firms for its sulforaphane product. APT Trans, the consortium of drug developers based in the Biohub at Alderley Park, which comprises of Aptus Clinical, Apconix and Seda

Read more
17 Jan 2017 12:35

Richard Moulson to join Evgen Pharma as CFO

(ShareCast News) - Clinical-stage drug development company Evgen Pharma announced the appointment of experienced healthcare executive Richard Moulson as its chief financial officer on Tuesday. The AIM-traded firm said Moulson was joining immediately as CFO-designate for a handover period to 28 Febru

Read more
11 Jan 2017 09:23

Evgen Pharma receives go ahead for haemorrhage drug trial

(ShareCast News) - Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has received a positive interim safety review from the independent Data Safety Monitoring Board (DSMB) for its Phase II double-blind placebo-controlled SAS trial

Read more
11 Jan 2017 09:17

Evgen Pharma Gets Positive Review For SFX-01 Phase II Study

Read more
17 Aug 2016 10:49

Evgen Pharma receives approval for breast cancer study

(ShareCast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that it has received a Clinical Trial Approval from the UK's regulatory agency for the commencement of its Phase II clinical trial of SFX-01 in breast cancer. The AIM-traded firm said patient recruitment w

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.